Posted by MoneyMakers > 30 minutes ago | Report Abuse AngTK definitely spoil forum BS long2 I usually ignore his nonsense (like this morning) ------------------
Yesterday morning nice public holiday but who so lonely and nothing better to do here and start attacking ATK ah?
Aiya see your own 7000+ posts' track record la. It is common knowledge that MM goes to many other i3 forums spewing rubbish, sickness, doing her roti prata evil tactics (fear monger, promote, then fear monger after she sold), attacking others with false accusations. I remember got people chasing her from other forum come into GenB forum hammering her like "Ah Loong take parang chasing debtor".
Super Good news ! More & more companies rushing to be listed into KLSE ! There are 6 companies going to be listed in KLSE for July & early August 2023 !
Posted by Michael_chan2022 > 3 hours ago | Report Abuse Seasonal trader will be back after the six state elections ---------------
Yes @Michael safer to buy after PH gets a strong mandate via state elections. If PN green wave, i will probably sell my MYR change back into SGD n not touch KLCI.
@ATK, the uncertainty in the markets can be stressful... take a break, and hopefully things will turn out more positively after the state election. We shall see.
TauRx’s drug candidate offers promise In an effort to neutralize the effect of aggregation of tau protein in the brain, life science company TauRx Therapeutics, headquartered in Singapore, has developed an oral inhibitor of the protein, to mitigate Alzheimer’s disease. A phase 3 clinical trial was announced to have observed promising results, in October last year.
In the LUCIDITY study, the drug candidate hydromethylthionine mesylate (HMTM), which was given to patients with mild to moderate forms of the disease, demonstrated a significant reduction in disease progression in patients, which was measured by changes in cognitive decline and brain atrophy.
“This is the first time any treatment has produced evidence of sustained improvement over the individual’s own pre-treatment baseline lasting 18 months at an early clinically detectable stage of AD, and stabilization of disease progression at more severe stages,” said Claude Wischik, executive chairman and co-founder of TauRx.
“Tau pathology of the disease is now recognized as an important target for treatment, and it is encouraging that cognitive improvement is seen at such an early stage of the disease with a drug targeting Tau. The field has focused mainly on amyloid as a target for early intervention. Our data are consistent with the evidence that Tau pathology begins at least 20 years before clinical symptoms appear and is a viable first-line target for treatment.”
However, although the candidate’s safety profile remains consistent with previously published trial data, the recent study was unable to compare the drug’s efficacy against a placebo. This was because when treated with HMTM, urinary discoloration occurs, posing a challenge to administer an appropriate placebo. Despite TauRx using methylthioninium chloride (MTC) – a dye used to treat a blood disorder – in its control group, those dosed with MTC were “unexpectedly found to have blood levels of active drug above the threshold needed to produce a clinical effect.” While this is the case, the company plans to go ahead with filing for FDA authorization.
Posted by MoneyMakers > 43 seconds ago | Report Abuse Investor alrdy accept TauRx fail (FF dont care TauRx - just want run from PH madani) Alrdy 1month stuck boring range - FF wait&see if PH madani disaster get worse -------------------
Aiyo old demented retiree how many times professional already told you HMTM works so beautifully.
1. HMTM already proven in phase 3 it can totally halt AD cognitive decline + 20% improvement in cognitive scores VS Lecanemab's 27% slowdown in decline but continue to decline at 73%.
2. HMTM has minimal side effects VS high brain bleeding chances including numerous death cases for Lecanemab
3. HMTM slows down brain atrophy (shrinkage) VS Lecanemab's accelerated brain shrinkage. This is definitely going in the wrong direction of how a good AD drug shd perform. ATK is expecting major efficacy and safety fiascos for Lecanemab in future.
4. HMTM at USD10k/ year VS Lecanemab's USD26k/yr treatment cost.
5, HMTM orally taken drug twice a day at home VS Lecanemab's twice a month infusion (like kidney dialysis) in hospital with multiple brain scans required for constant costly monitoring for ARIA.
There is no suitable placebo candidate to give out a blue pee for trial hence the next confirmatory trial to secure FULL APPROVAL will be no placebo open label trial compared to historical placebo data for all AD clinical trials. HMTM is in the process of securing Conditional Approval / Accelerated Approval. We are very confident of our data to secure the CAs and AA. HMTM (2nd generation drug formula) is derived from MTC (Taurx's discarded first generation drug). Even using a super super low dose of MTC as placebo can surprisingly yield some drug efficacy. See how powerful drug efficacy MTC/HMTM posses??? HMTM is the best solution to halt global AD pandemic.
Aiya this MM scared can just cutloss la. Spewing BS here daily complaining and giving false info. Dont trade stocks la better put your meagre retirement money into FD safer, Later another kena selldown you may lose 30 to 40 sen ya.
Posted by MoneyMakers > 9 minutes ago | Report Abuse AngTK Let me simplify 4 dummy In exp, TauRx 2.0 & placebo (TauRx 1.0) show similar effectiveness Since TauRx 1.0 considered failure (fail experiment/ineffective) - then TauRx 2.0 also fail lo ------------------
Aiyo this MM really a dummy. MTC REMBER phase 2 trial was good also. But new formula HMTM even better. ATK explain until mouth dry liow MM still a dummy. There are approvals called CA and AA which Taurx is applying for HMTM to commercialise the drug first, followed by another non-placebo retrial. HMTM can work very well and can even reverse AD progression. Aiya you better go and take Lecanemab la.
Posted by MoneyMakers > 8 seconds ago | Report Abuse AngTK Nobody care phase 2 trial (small experiment) - TauRx 1.0 fail phase 3 TauRx 2.0 similar effectiveness as TauRx 1.0 = both useless -----------------
From all the trials can see HMTM is very effective and it has always been the placebo issues to produce the blue pee effect for trial patients blinding purposes. The next trial will have no more placebo pill involvement, confirm can see stunningly solid clean result. Retrial result confirm no problem. We are on the way to secure all the CAs and AA to start selling HMTM. Professionals will advice their friends/ relatives that kena AD to take HMTM. Only amateur MM will take Lecanemab. Lecanemab treatment Is going to be the best life experience for her.
Posted by MoneyMakers > 9 seconds ago | Report Abuse AngTK Last time TauRx 1.0 didnt fail phase3 trial bcoz placebo issue (simply ineffective/useless) TauRx 2.0 similar effectiveness as TauRx 1.0 = both useless ------------
You demented forgot liow? Go n do more research first la. Do register yourself for lecanemab treatment ok?
Dr Sonya Miller, Head of Medical Affairs at TauRx, and Professor Bjoern Schelter, CEO at GT Diagnostics and Chief Analytics Officer at TauRx, discuss what’s needed to create a more effective dementia diagnosis process and get treatment to those who need it in the timeliest manner possible.
Posted by Michael_chan2022 > 20 minutes ago | Report Abuse @ATK, I'm sailing with Seatrium.... ----------------
Seatrium... has been my favourite shorting stock 10 years ago. I thought it was already very cheap and stopped shorting after 2016. My stock trading sifu placed both long-term and shorter term trading shorts. Those long term shorts he held on for many years all the way down until rights issue then he covered back. Really a big huat trade for him. A lot of long term retail investors in SGX kena chaotar by Noble and Submarine. Who would have expected cheap become cheaper, and cheaper and cheaper.... end up become like toilet paper. KNN ex-STI component stock. I made good money trading Noble some years ago. Traded long on Noble during the bullish days, shorting it during iceberg report days. So cheap liow then suddenly Muddy Waters still dare to come in and continue shorting... and they made a huge pile! Wah... really professional shorting whale. My sifu said before: "Stocks are never too low to short". I will always remember that!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
1invest1
1,467 posts
Posted by 1invest1 > 2023-06-30 16:16 | Report Abuse
ok, let's get GB go lower.
How about 3.50
as more interest rate hikes coming soon.
@AngTayKor,
@choysun,
@Destiny L &
others can then load up.